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Background: Mesenchymal stem cells (MSCs) have the potential to differentiate into specialized cell lineages such
as osteoblasts and adipocytes in vitro. There exists a reciprocal relationship between osteogenic and adipogenic
differentiation of MSCs that an osteogenic phenotype occurs at the expense of an adipogenic phenotype and vice
versa, which in turn influence one another’s phenotype through negative feedback loops. Thus, it is important to
understand what signaling molecules modulate the lineage commitment of MSCs. Protein kinase C (PKC) plays a
central role in cellular signal transduction for mediating diverse biological functions, and dysregulation of PKC
activity is involved in various metabolic diseases including cancer, diabetes, and heart disease. Although the role of
individual PKC isoforms has been investigated in various fields, the potential role of PKC in bone metabolism is not
completely understood. In this study, we investigated the potential role of PKCδ in osteogenic lineage commitment
of human bone marrow-derived mesenchymal stem cells (hBMSCs).
Results: We observed that expression and phosphorylation of PKCδ were increased during osteogenic differentiation
of hBMSCs. Pharmacological inhibition and genetic ablation of PKCδ in hBMSCs resulted in a significant attenuation of
osteogenic differentiation as evidenced by reduced ALP activity and ECM mineralization, as well as down-regulation of
the expression of osteoblast-specific genes. These effects were also accompanied by induction of adipogenic
differentiation and up-regulation of the expression of adipocyte-specific genes involved in lipid synthesis in osteogenic
induction of hBMSCs. Additionally, the activation of AMPK, which is a key cellular energy sensor, induced osteogenesis
of hBMSCs. However, the inhibition of AMPK activity by compound C did not affect the activation of PKCδ at all,
indicating that there is no direct correlation between AMPK and PKCδ in osteogenesis of hBMSCs.
Conclusions: These results suggest that PKCδ is a critical regulator for the balance between osteogenesis and
adipogenesis of hBMSCs and thus has a potential novel therapeutic target for the treatment of metabolic bone
diseases.
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Human mesenchymal stem cells (hMSCs), also known as
adult multipotent stem cells, have been identified in the
bone marrow and in various tissues such as adipose tissue,
synovial tissue, periosteum, perichondrium and cartilage
[1]. These cells have the capacity of self-renewal and the
potential to differentiate into specialized cell lineages,* Correspondence: dckang@hallym.ac.kr
1Ilsong Institute of Life Science, Hallym University, Anyang, Gyeonggi-do
431-060, Republic of Korea
2Department of Biomedical Gerontology, Graduate School of Hallym
University, Chuncheon, Gangwon-do 200-702, Republic of Korea
© 2014 Lee et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.including osteoblasts, adipocytes and chondrocytes under
permissive conditions [2]. Importantly, the potential of
these cells in cell-based regenerative therapies hold tre-
mendous promise for the treatment of various diseases
including osteogenesis imperfecta, cardiovascular disease,
and neurological disease [3,4]. Hence, it is important to
understand the regulatory mechanism responsible for
their differentiation.
Mature osteoblasts, which terminally differentiate into
osteocytes, play an essential role for the initiation of bone
mineralization and formation, leading to increased bone
regeneration rate. Mineralized bone matrix is considered. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Lee et al. BMC Cell Biology 2014, 15:42 Page 2 of 12
http://www.biomedcentral.com/1471-2121/15/42to be a hallmark of the final phase of osteogenic differenti-
ation [5]. These processes are tightly controlled by the ex-
pression of osteogenesis-related genes, including alkaline
phosphatase (ALP), which is not restricted to osteogenic
cells and is also expressed in other cell types including em-
bryonic stem cells, runt-related transcription factor 2
(RUNX2), osteocalcin (OCN), and osterix (OSX) [6]. Bone
formation is dependent on the recruitment of an adequate
number of osteoblasts and their osteogenic activity [7].
However, the impaired bone formation, which is function-
ally associated with decreased osteoblastic bone-forming
activity, contributes to the pathogenesis of metabolic bone
diseases including osteoporosis, osteomalacia, and Paget’s
disease [8]. Therefore, understanding the molecular mech-
anisms underlying bone formation has emerged as a po-
tential therapeutic approach for the treatment of these
diseases.
Protein kinase C (PKC) is a family of serine/threonine
protein kinases that is known to be involved in a multi-
tude of physiological processes such as cell proliferation,
differentiation, apoptosis, and survival. The PKC family
consists of at least 11 distinct isoforms in mammals.
PKCs are classified into three groups depending on their
structure and cofactor requirements: Ca2+/diacylglycerol
(DAG)-dependent classical PKC (α, β1, β2 and γ), DAG-
dependent novel PKC (δ, ε, η, θ and μ), and Ca2+/DAG-
independent atypical PKC (λ/ι and ζ). The PKC activity
is also tightly regulated by its association with protein
complexes and its intracellular distribution [9-12]. Re-
cently, several studies have reported that specific PKC
isoforms are involved in embryonic bone formation and
remodeling by affecting both osteoblast and osteoclast
activity [13-16]. These findings indicate that PKC could
be targeted to drive osteogenesis in hMSCs. However,
the exact mechanism of osteogenic differentiation of
hMSCs regulated by PKC is still not fully understood.
In addition, the AMPK signaling pathway, a master
regulator of cellular energy homeostasis, is involved in
bone metabolism. Activation of AMPK stimulates bone
formation in vitro, while the lack of either α or β subunit
of AMPK results in reduced bone mass in mice [17].
AMPK has been reported as an upstream kinase of PKCδ
in various cell types [18,19]. Although these studies sug-
gest the possibility that AMPK/PKCδ pathway could par-
ticipate in the MSC differentiation, there are no reports
available as yet of the interrelationship between AMPK
and PKCδ during differentiation into osteogenic lineage.
The aim of our study was to determine the role of spe-
cific PKC isoform in osteogenic differentiation. In this
study, we employed human bone marrow-derived mes-
enchymal stem cells (hBMSCs). We identified that un-
like other PKC isoforms, PKCδ mRNA and protein
levels steadily increased during osteogenic differentiation
of hBMSCs and further examined the role of PKCδ inthe regulation of their osteogenic differentiation. We
found that both pharmacological and genetic inhibition
of PKCδ impaired osteogenic differentiation of hBMSCs,
including a decreased ALP activity and matrix miner-
alization, as well as the down-regulation of osteogenic
marker gene expression. Interestingly, we found that ac-
tivation of AMPK, similar to changes in PKCδ expres-
sion, induced osteogenesis of hBMSCs. However, there
was no direct correlation between PKCδ and AMPK
under our experimental condition. We further showed
that the effect of PKCδ inhibition on hBMSC osteogenic
differentiation was exerted through a positive regulation
of adipogenic differentiation. Notably, both pharmaco-
logical and genetic inhibition of PKCδ in hBMSCs exhib-
ited more adipogenic phenotype than their counterparts
under osteogenic condition. Thus, these findings demon-
strate the potential importance of PKCδ in directing
hBMSC differentiation and provide a promising new av-
enue for the treatment of metabolic bone diseases.
Methods
Cell culture
All cell culture media and supplements were obtained
from Gibco (Carlsbad, CA, USA), unless otherwise indi-
cated. Human bone marrow-derived mesenchymal stem
cells (hBMSCs) were purchased from ScienCell Research
Laboratories (Cat. No. 7500; Carlsbad, CA, USA) and
maintained in growth medium (GM) consisting of α-
Minimum Essential Medium (α-MEM) supplemented
with 16.5% fetal bovine serum (FBS) and antibiotics (100
units/mL penicillin and 100 μg/mL streptomycin) at 37°C
in a humidified atmosphere of 5% CO2 and 95% air. Cells
between passages 3 and 10 were used for all experiments.
For lentivirus production, HEK293T cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) containing
10% FBS and antibiotics (100 units/mL penicillin and
100 μg/mL streptomycin) at 37°C in a humidified atmos-
phere of 5% CO2 and 95% air.
Osteogenic induction and alizarin red S staining
For osteogenic differentiation, hBMSCs were plated at
density of 3 × 105 cells/well on 6-well plates or 1 × 104
cells/well on 96-well plates. After 2 days of incubation at
which 100% confluent, hBMSCs were cultured for an
additional 14 days in osteogenic differentiation medium
(ODM) consisting of α-MEM supplemented with 10%
FBS, 100 nM dexamethasone (Sigma-Aldrich, St. Louis,
MO, USA), 10 mM β-glycerophosphate (Sigma-Aldrich,
St. Louis, MO, USA), 50 μM ascorbic-2-phosphate (Sigma-
Aldrich, St. Louis, MO, USA), 100 units/mL penicillin and
100 μg/mL streptomycin and then treated with either ve-
hicle (DMSO; Sigma-Aldrich, St. Louis, MO, USA), or rot-
tlerin (Calbiochem, La Jolla, CA, USA), or compound C
(Calbiochem, La Jolla, CA, USA), respectively. Fresh
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tiation of hBMSCs was assessed by alizarin red S staining
for the presence of calcium deposits. Briefly, the cells were
washed twice with PBS (Sigma-Aldrich, St. Louis, MO,
USA), fixed with 4% formaldehyde (Sigma-Aldrich, St.
Louis, MO, USA) for 30 min at room temperature, rinsed
with distilled water, and then stained with 2% (w/v) ali-
zarin red S (Sigma-Aldrich, St. Louis, MO, USA) dissolved
in distilled water (pH 4.2; adjusted with 10% ammonium
hydroxide [Sigma-Aldrich, St. Louis, MO, USA]) for
45 min. Cells were then washed extensively with distilled
water and examined for mineralization of extracellular
matrix (ECM). After imaging, the dye was eluted with
10% (w/v) cetylpyridinium chloride monohydrate (Sigma-
Aldrich, St. Louis, MO, USA) in 10 mM sodium phos-
phate (pH 7.0; Sigma-Aldrich, St. Louis, MO, USA) for 1 h
at room temperature, and the absorbance was measured
at 570 nm using a Multiskan™ GO microplate reader
(Thermo Scientific, Waltham, MA, USA).
Oil red O staining
The hBMSCs were cultured in ODM as described above
for 14 days. Accumulation of lipid droplets in differenti-
ated adipocytes from hBMSCs was assessed by oil red O
staining. Briefly, cells were washed twice with PBS and
fixed with 4% formaldehyde for 30 min at room tem-
perature. After washing two times with PBS, cells were
stained with 0.6% oil red O (Sigma-Aldrich, St. Louis, MO,
USA) in isopropanol (Sigma-Aldrich, St. Louis, MO, USA)
for 2 h at room temperature. The stain was then removed,
and the cells were rinsed five times with distilled water.
The stained lipid droplets were observed with an inverted
phase-contrast microscope (Olympus, Tokyo, Japan).
ALP activity assay
Cellular ALP activity as an early marker of osteogenic
differentiation was assessed at day 7. Cells were washed
twice with PBS and then lysed with protein lysis buffer
containing 50 mM Tris–HCl pH 7.4 (Promega, Madison,
WI, USA), 150 mM NaCl (Sigma-Aldrich, St. Louis, MO,
USA), 1 mM EDTA (Sigma-Aldrich, St. Louis, MO, USA),
and 1% NP-40 (Sigma-Aldrich, St. Louis, MO, USA). ALP
activity was determined colorimetrically by incubating
protein lysates with the substrate p-nitrophenyl phosphate
(Sigma-Aldrich, St. Louis, MO, USA) in a 96-well plate at
37°C for 30 min. The absorbance was measured at 405 nm
and normalized against the corresponding protein concen-
trations. The values were expressed as fold change relative
to undifferentiated cells.
RNA extraction and reverse transcription PCR (RT-PCR)
Total RNA was extracted from cells using Trizol reagent
(Invitrogen, Carlsbad, CA, USA), and cDNA was reverse-
transcribed from 2 μg of total RNA with the GoScript™Reverse Transcription System (Promega, Madison, WI,
USA) according to the manufacturer’s instructions. The
primer sequences used for PCR are given in Additional
file 1: Table S1. The PCR was performed as follows: one
cycle of 3 min at 95°C; 35 cycles of denaturation at 95°C
for 30 sec, annealing at 56°C for 30 sec and extension at
72°C for 45 sec; and then a final cycle of 5 min at 72°C.
The PCR products were loaded onto 1% agarose gel con-
taining ethidium bromide (Promega, Madison, WI, USA).
The expression data were normalized to β-actin mRNA
levels in each sample.
Western blot analysis
Cells were washed twice with PBS and lysed in RIPA lysis
buffer including 50 mM Tris–HCl pH 7.4, 150 mM NaCl,
1 mM EDTA, 1% NP-40, 0.1% SDS (USB, Cleveland, OH,
USA), 0.5% sodium deoxycholate (Sigma-Aldrich, St.
Louis, MO, USA), 1 mM PMSF (Sigma-Aldrich, St. Louis,
MO, USA), protease inhibitor cocktail (Pierce Biotechnol-
ogy, Rockford, IL, USA), and phosphatase inhibitors con-
taining 10 mM sodium fluoride (Sigma-Aldrich, St. Louis,
MO, USA), 2 mM sodium orthovanadate (Sigma-Aldrich,
St. Louis, MO, USA), 10 mM sodium pyrophosphate
(Sigma-Aldrich, St. Louis, MO, USA). Protein concentra-
tion in the supernatant was determined using the Bradford
assay (Bio-Rad Laboratories, Hercules, CA, USA). Equal
amounts of total proteins (25 μg) were separated on 10%
SDS-PAGE and transferred onto Hybond-ECL nitrocellu-
lose membranes (Amersham, Arlington Heights, IL, USA).
The membranes were blocked with Tris-buffered saline-
Tween 20 (TBS-T: 10 mM Tris–HCl pH 7.6, 150 mM
NaCl, and 0.1% Tween 20 [USB, Cleveland, OH, USA])
containing 5% nonfat dry milk (Becton Dickson and Com-
pany, Sparks, MD, USA) for 1 h at room temperature and
incubated overnight at 4°C with specific primary anti-
bodies diluted in TBS-T. The membranes were washed
three times withTBS-T and then incubated with the appro-
priate horseradish peroxidase (HRP)-conjugated secondary
antibodies for 1 h at room temperature. The blots were
visualized using ECL detection reagents (Advansta, Menlo
Park, CA, USA) and exposed to photographic films (Agfa
HealthCare NV, Mortsel, Belgium). The antibody combina-
tions and dilutions are detailed in Additional file 2: Table
S2–1 and Table S2–2.
Lentivirus production and titration
Lentiviral shRNA expression vectors for non-targeting
and human PKCδ (PRKCD) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Lentivirus was produced by
using the calcium phosphate transfection protocol and the
viral titre was measured as described previously [20].
Briefly, HEK293T cells were seeded into 10-cm dishes at a
density of 5 × 106 cells/dish and incubated overnight until
they reached approximately 80% confluence. The cells
Lee et al. BMC Cell Biology 2014, 15:42 Page 4 of 12
http://www.biomedcentral.com/1471-2121/15/42were transfected with 10 μg of the shRNA transfer vector,
7.5 μg of psPAX2 viral packaging plasmid and 2.5 μg of
pMD2G viral envelop plasmid in a 10-cm dish. Viral su-
pernatants were collected at 48 h after transfection and
used for transduction of target cells in the presence of
8 μg/mL polybrene (hexadimethrine bromide; Sigma-
Aldrich, St. Louis, MO, USA) for 24 h. Cells were cultured
in the presence of 2 μg/mL puromycin (Sigma-Aldrich, St.
Louis, MO, USA) to select shRNA-transduced cells for
3 days and then used for differentiation. The viral titre was
determined by relative vector particle numbers based on
virion RNA and calculated according to the following for-
mula: relative vector particles/mL (VP/mL) = (C ×D)/V,
where C = number of RNA copies, D = dilution of vector
preparation (including the dilution into the PCR), and
V = volume in mL.
Statistical analysis
All data were expressed as the mean ± S.E. Differences be-
tween groups were examined for statistical significance
using Student’s t-test and analysis of variance (ANOVA).
The difference was considered to be significant if P <0.05.
Results
Up-regulation of PKCδ during osteogenic differentiation
in hBMSCs
To examine the expression pattern of PKCδ during
the osteogenesis of hBMSCs, we used an osteogenicFigure 1 Up-regulation of PKCδ during osteogenic differentiation in hB
indicated times. The osteogenic differentiation potential of hBMSCs was estim
osteogenic markers: ALP and OC (B) at the indicated times. (C) The mRNA exp
after osteogenic induction of hBMSCs. (D) The protein level of PKCδ was dete
indicated times after osteogenic induction of hBMSCs. Data shown are meansdifferentiation model in which hBMSCs were incubated in
either GM or ODM for 1, 4, 7, 10, and 14 days. Osteo-
genic differentiation potential of hBMSCs was confirmed
by a significant increase in ALP activity and the mRNA
levels of both early and late osteogenic markers, ALP and
OCN, respectively (Figure 1A and B). This was associated
with the mRNA and protein expressions of PKCδ and its
phosphorylation, which was significantly up-regulated at
7, 10, and 14 days after the initiation of osteogenic induc-
tion (Figure 1C and D). Noticeably, the expression pattern
of PKCδ is in stark contrast to that of PKCα under the
same condition (Figure 1C), suggesting that among the
PKC isoforms, PKCδ may act as a switch of osteogenic dif-
ferentiation of hBMSCs. Taken together, these results indi-
cate that osteogenic differentiation of hBMSCs is closely
accompanied with expression and activation of PKCδ.
Inhibition of PKCδ activity attenuates osteogenic
differentiation in hBMSCs
To determine whether PKCδ activity is required for
osteogenic differentiation of hBMSCs, we treated with
various concentrations of rottlerin, a PKCδ-specific in-
hibitor, during osteogenic differentiation of hBMSCs. At
7 days after induction of differentiation, the intracellular
ALP activity was evaluated by colorimetric assay. Treat-
ment with rottlerin significantly decreased ALP activity
in a dose-dependent manner (Figure 2A and B). After
14 days of induction, the mineralized matrix depositionMSCs. (A-D) Post-confluent hBMSCs were cultured in GM or ODM for the
ated by ALP activity assay (A) and RT-PCR analysis of early and late
ression of PKCα and δ were determined by RT-PCR at the indicated times
rmined by western blot analysis with the specified antibodies at the
± S.E. (*P <0.05 versus GM) of three independent experiments.
Figure 2 Inhibition of PKCδ activity attenuates osteogenic differentiation in hBMSCs. (A) Post-confluent hBMSCs were cultured in GM or
ODM at the indicated concentrations of rottlerin, a specific PKCδ inhibitor. ALP activity was determined after osteogenic induction of
hBMSCs for 7 days. (B) For quantitative determination of ALP activity, the absorbance at 405 nm of cell extracts was measured and
expressed as the fold change of treated cells over vehicle-treated cells in GM. (C) Post-confluent hBMSCs were cultured in GM or ODM with
2 μM rottlerin. Alizarin red S staining was performed to monitor mineralization of hBMSCs after osteogenic induction for 14 days. (D) For
quantitative determination, the absorbance of alizarin red S was measured at 570 nm and expressed as the fold change of treated cells over
vehicle-treated cells in GM. (E) Post-confluent hBMSCs were cultured in GM or ODM with 2 μM rottlerin, and then harvested at 14 days. The
mRNA expression of osteogenesis-related genes, including ALP, RUNX2, and OCN, was estimated by RT-PCR. The representative images from
three independent experiments are shown. Data shown are means ± S.E. (*P <0.05 versus vehicle-treated cells in ODM) of three
independent experiments.
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2 μM rottlerin completely blocked ECM mineralization
(Figure 2C and D). To further confirm the effects of
PKCδ inhibition on osteogenic differentiation, we ana-
lyzed the gene expression pattern of major osteogenic
markers such as ALP, RUNX2, and OCN. As shown in
Figure 2E, the mRNA levels of ALP, RUNX2, and OCN
were significantly decreased by treatment with 2 μMrottlerin. These results suggest that PKCδ activation
plays an important role in promoting osteogenic differ-
entiation of hBMSCs.
Knockdown of PKCδ inhibits osteogenic differentiation
in hBMSCs
Although the direct inhibition of PKCδ activity by rottlerin
has been demonstrated, a major problem has been its
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ther determine the functional role of PKCδ in osteogenic
differentiation, we applied lentivirus-mediated shRNA
transduction to reduce PKCδ expression in hBMSCs. The
knockdown efficacy of PKCδ shRNA was confirmed by
RT-PCR and western blot analysis (Figure 3A and B). After
7 days of osteogenic differentiation, the ALP activity was
significantly down-regulated in PKCδ shRNA-transduced
cells compared with control shRNA-transduced cells
(Figure 3C and D). We also observed that the mineralized
matrix deposition was markedly suppressed in PKCδ
shRNA-transduced cells after 14 days of osteogenic induc-
tion (Figure 3E and F). Additionally, the up-regulation of
osteogenesis-specific genes during osteogenic differenti-
ation was decreased in PKCδ shRNA-transduced cells
(Figure 3G). Taken together, these results support the con-
clusion that PKCδ is necessary to trigger osteogenic differ-
entiation of hBMSCs in a direct manner.
AMPK activation is required for osteogenic differentiation
of hBMSCs independently of PKCδ
AMPK has been reported as an upstream kinase of
PKCδ in various cell types [18,19]. Based on the previous
observations, we investigated whether activation of AMPK
might contribute to the osteogenic differentiation of
hBMSCs, together with activation of PKCδ. The activation
of AMPK was dramatically elevated on day 4 and main-
tained at a high level until day 14 after the initiation of
osteogenic induction (Figure 4A). After 14 days of osteo-
genic induction, we observed that the mRNA levels of
osteogenic differentiation markers, including ALP, RUNX2,
and OCN, were completely impaired in the cells treated
with 10 μM compound C, a specific inhibitor of AMPK
(Figure 4B). Subsequently, we also observed that treatment
with 10 μM compound C drastically reduced ALP activity
(Figure 4C and D), which is consistent with the inhibitory
effect of compound C on the formation of mineralized
ECM (Figure 4E and F). Therefore, these results suggest
that AMPK is potentially capable of stimulating osteogenic
differentiation of hBMSCs. However, the inhibition of
AMPK activity by compound C did not affect the activity
of PKCδ at all, as assessed by western blot analysis, indi-
cating that there is no direct correlation between AMPK
and PKCδ in osteogenesis of hBMSCs (data not shown).
Suppression of PKCδ-mediated osteogenic differentiation
enhances the adipogenic phenotype of hBMSCs
The clinical and experimental implications have revealed
an inverse relationship between osteogenic and adipo-
genic differentiation in bone marrow [22-25]. The inhib-
ition of PKCδ in mouse preadipocytes leads to enhanced
adipogenic differentiation by activating the expression of
adipocyte-specific genes [26,27]. Therefore, we examined
whether the effect of PKCδ inhibition on osteogenicdifferentiation causes induction of adipogenic differenti-
ation of hBMSCs. Treatment with rottlerin induced ac-
cumulation of lipid droplets under osteogenic condition
(Figure 5A). Similar to the lipid accumulation, RT-PCR
results showed that the mRNA expression levels of all
three adipogenic markers PPARγ, C/EBPα, and aP2 were
increased in hBMSCs treated with rottlerin under osteo-
genic condition (Figure 5B). The protein expression
levels of PPARγ and C/EBPα were also altered in the
same manner as mRNA (Figure 5C). To further investi-
gate the effect of PKCδ expression on adipogenic differen-
tiation, we examined adipogenic differentiation potential
of PKCδ-knockdown hBMSCs in osteogenic condition.
Consistent with the effect of rottlerin that inhibition of
PKCδ activity influences osteogenic differentiation by pro-
moting PPARγ signaling, the lipid droplet accumulation
and the expression of adipogenesis-specific markers at
both the mRNA and protein levels were markedly elevated
in PKCδ shRNA-transduced cells compared with control
shRNA-transduced cells (Figure 5D, E, and F). Interest-
ingly, identical to the effects of PKCδ inhibition, treatment
with compound C increased the formation of lipid droplet
and the expression of adipogenesis-specific genes at both
the mRNA and protein levels under osteogenic condition
(Figure 5G, H, and I). Collectively, these results strongly
suggest that the effect of PKCδ inhibition on osteogenic
differentiation could be sufficiently translated into adipo-
genic differentiation of hBMSCs.
Discussion
PKC has been implicated in the regulation of a variety of
cellular processes such as cell proliferation, differenti-
ation, apoptosis, and survival. It was previously reported
that modulation of PKC activity has several therapeutic
effects in cancer and other metabolic diseases such as
anti-tumorigenic properties, improved glucose metabol-
ism and cardioprotective benefits [28]. However, the
exact role of PKC in bone metabolism remains to be
fully elucidated. In this study, we have identified the po-
tential role of PKCδ as a key modulator of hBMSC dif-
ferentiation. Our results indicate that the expression and
phosphorylation of PKCδ were markedly elevated during
osteogenic differentiation of hBMSCs, leading to a sig-
nificant increase in ALP activity and matrix miner-
alization, as well as up-regulation of the expression of
osteogenesis-specific genes. Moreover, inhibition of PKCδ
not only inhibited osteogenic differentiation, but also pro-
moted lipid accumulation in hBMSCs through increased
expression of adipogenesis-specific marker genes under
osteogenic condition. These findings suggest that the
stimulatory effect of PKCδ on osteogenic differentiation of
hBMSCs appears to have occurred, at least in part by sup-
pression of adipogenesis signaling pathway. Taken all to-
gether, this is the first experimental study to support that
Figure 3 (See legend on next page.)
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Figure 3 Knockdown of PKCδ inhibits osteogenic differentiation in hBMSCs. The knockdown efficacy of PKCδ shRNA was assessed by
RT-PCR (A) and western blot analysis (B). (C) Control shRNA- or PKCδ shRNA-transduced cells were cultured in GM or ODM. ALP activity assay was
determined after osteogenic induction of hBMSCs for 7 days. (D) For quantitative determination, the absorbance at 405 nm of ALP reaction was
measured and expressed as the fold change of cultured cells over control shRNA-transduced cells in GM. (E) Control shRNA- or PKCδ shRNA-transduced
cells were cultured in GM or ODM, and differentiated osteoblasts were stained with alizarin red S. (F) For quantitative determination, the absorbance of
alizarin red S was measured at 570 nm and expressed as the fold change of cultured cells over control shRNA-transduced cells in GM.
(G) The mRNA expression of ALP, RUNX2, and OCN was estimated by RT-PCR. The representative images from three independent experiments
are shown. Data shown are means ± S.E. (*P <0.05 versus control shRNA-transduced cells in ODM) of three independent experiments.
Lee et al. BMC Cell Biology 2014, 15:42 Page 8 of 12
http://www.biomedcentral.com/1471-2121/15/42PKCδ plays critical role in regulating osteogenic vs adipo-
genic differentiation of hBMSCs.
The expression pattern of PKC isofoms in different
osteogenic precursor cell lines, including human MSCs
and mouse osteoblastic MC3T3-E1 cells, has been previ-
ously investigated by several groups [29-31]. It has also
been demonstrated that specific PKC isoforms have a
role in regulating osteoblast activity in vitro (in cultured
cells) and in vivo (in animal models). PKCα activation
but not PKCβ suppressed osteogenic differentiation
[14], whereas PKCδ promoted osteogenic differentiation
through the transactivation of RUNX2 [32,33]. More-
over, the decreased bone formation during embryonic
skeletal development has been shown in PKCδ knock-
out mice, probably due to delaying the onset of Osx ex-
pression [13]. We found that the increased expression
of PKCδ is in contrast to the highly restricted expres-
sion of PKCα during osteogenic induction of hBMSCs
(Figure 1). This is consistent with the previous findings
that overexpression of PKCδ significantly decreased
PKCα activity, while expression of dominant negative
mutant of PKCδ significantly increased it in vitro [34].
The expression pattern of PKCδ positively correlates
with the rapid induction of ALP acitivty and the up-
regulation of early and late osteogenic marker genes,
ALP and OCN, respectively. Therefore, these data sug-
gest a potential role of PKCδ in the regulatory mechan-
ism of osteogenic differentiation.
In the present study, suppression of PKCδ activity with
a specific inhibitor, rottlerin, or depletion of PKCδ by
lentiviral shRNA in hBMSCs inhibited induction of
osteogenic differentiation (Figure 2 and Figure 3). We
found that activation of PKCδ during osteogenic differ-
entiation of hBMSCs leads to increased expression of
RUNX2 and its downstream targets, ALP and OCN,
which are known to be regulated by RUNX2. Moreover,
inhibition of PKCδ using rottlerin or PKCδ shRNA com-
pletely reversed the osteogenic response of hBMSCs,
suggesting that PKCδ functions as a potent activator of
RUNX2 expression in bone development. Considerable
evidence now suggests that PKCδ-dependent mechanism
plays an important role in bone development. Several
studies have indicated that osteogenic differentiation isassociated with an increase in RUNX2 transcriptional
activity through phosphorylation of RUNX2 at key resi-
dues by PKCδ, without changing the protein levels of
RUNX2 [35,36]. The translocation of PKCδ from the
cytoplasm to the nucleus in response to osteogenic con-
dition could indeed influence the phosphorylation status
and modulation of RUNX2 DNA-binding activity, which
are concomitant with the enhanced OCN gene tran-
scription [32,33,37]. Thus, although the functional inter-
action between PKCδ and RUNX2 was not assessed in
the present study, it is possible that PKCδ could be dir-
ectly responsible for enhancing osteogenic differentiation
through both the regulation of RUNX2 expression and
transcriptional activity in hBMSCs.
In terms of identifying the novel regulatory mecha-
nisms that mediate the stimulatory effect of PKCδ on
osteogenic differentiation of hBMSCs, it is worth noting
that the effect of PKCδ on the osteogenic differentiation
of hBMSCs occurs in parallel with an increased AMPK
activity (Figure 4). Indeed, we found that AMPK activa-
tion increased markedly during osteogenic differenti-
ation of hBMSCs and inhibition of AMPK reduced the
gene expression of osteogenic markers in osteogenesis
assays in vitro, including ALP activity and matrix min-
eralization. These results indicate an important role for
AMPK in osteogenic differentiation of hBMSCs. A posi-
tive role of AMPK in driving and sustaining osteogenic
differentiation is supported by the prior reports that
AMPK activation facilitates bone formation by up-
regulating expression of osteogenic lineage-specific genes
[38,39]. Since both PKCδ and AMPK have a stimulating
effect on osteogenic differentiation of hBMSCs, whether a
direct connection between PKCδ and AMPK may syner-
gize to accelerate osteogenic program of hBMSCs is a
remaining question. Interestingly, AMPK was found to be
associated with PKCδ activation in monocytic and
lymphocytic cells [19]. In this study, although PKCδ and
AMPK activation have identical effects on the regula-
tion of hBMSC differentiation, no direct correlation
was found between these two kinases. Consequently,
PKCδ appears to coordinate osteogenic differentiation
in hBMSCs independently of AMPK pathway. Further
study is required to elucidate the novel upstream and
Figure 4 AMPK activation is required for osteogenic differentiation in hBMSCs independently of PKCδ. (A) Post-confluent hBMSCs were
cultured in GM or ODM for the indicated times. Cell lysates were prepared and subjected to western blot analysis using the indicated antibodies.
(B) Post-confluent hBMSCs were cultured in GM or ODM with 10 μM compound C, a specific inhibitor of AMPK, and then harvested after 14 days.
The mRNA expression of ALP, RUNX2, and OCN was estimated by RT-PCR. (C) Post-confluent hBMSCs were cultured in GM or ODM with 10 μM
compound C. After 7 days of osteogenic induction, ALP activity was determined by the ALP activity assay. (D) For quantitative determination,
the absorbance at 405 nm of ALP reaction was measured and expressed as the fold change of treated cells over vehicle-treated cells in GM.
(E) Post-confluent hBMSCs were cultured in GM or ODM with 10 μM compound C. Differentiated osteoblasts were stained with alizarin red S
after 14 days of osteogenic induction. (F) For quantitative determination, the absorbance of alizarin red S was measured at 570 nm and
expressed as the fold change of treated cells over vehicle-treated cells in GM. The representative images from three independent experiments
are shown. Data shown are means ± S.E. (*P <0.05 versus vehicle-treated cells in ODM) of three independent experiments.
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http://www.biomedcentral.com/1471-2121/15/42downstream effectors of PKCδ during osteogenic dif-
ferentiation of hBMSCs.
It is also noteworthy that inhibition of PKCδ using rot-
tlerin or PKCδ shRNA suppressed osteogenesis but pro-
moted adipogenesis of hBMSCs (Figure 5). These
biphasic effects of PKCδ on hBMSC differentiation are
likely to be partially explained by the inverse relationship
between osteogenesis and adipogenesis in the bonemarrow. It has been well established that the balance be-
tween osteogenesis and adipogenesis in MSCs depends
on different signaling pathways that converge on the
regulation of the two master transcription factors
RUNX2 and PPARγ. The osteogenic and adipogenic sig-
naling pathway may contribute to RUNX2 and PPARγ
expression through a mutually negative interconnection
[22-25]. Dysregulation of bone and fat formation is
Figure 5 Suppression of PKCδ-mediated osteogenic differentiation enhances the adipogenic phenotype of hBMSCs. Post-confluent
hBMSCs were cultured in ODM with 2 μM rottlerin (A) or 10 μM compound C (G). (D) Control shRNA- or PKCδ shRNA-transduced cells were
cultured in ODM. Differentiated adipocytes were stained with oil red O after 14 days of osteogenic induction and at magnification of x 100
photographed. (B, E, and H) After 14 days of osteogenic induction, RT-PCR was performed to estimate the mRNA expression of adipocyte-specific
genes, including PPARγ, C/EBPα, and aP2, in the indicated groups. (C, F, and I) After 14 days of osteogenic induction, the protein expression levels
of PPARγ and C/EBPα were determined by western blot analysis with the specified antibodies in the indicated groups. Data shown are representatives
of three independent experiments.
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http://www.biomedcentral.com/1471-2121/15/42implicated with a high incidence of both osteoporosis
and obesity [40,41]. We found PKCδ inhibition during
osteogenic differentiation of hBMSCs resulted in a pro-
nounced decrease in the expression of osteogenictranscription factor RUNX2 and up-regulation of major
adipogenic transcription factors PPARγ and C/EBPα.
These effects lead to suppression of bone formation and
decrease of bone mineral content, and the formation of
Figure 6 PKCδ regulates bone formation in a direct and indirect manner. The direct pathway is dependent on osteogenesis. The
endogenous PKCδ in hBMSCs strongly stimulates the RUNX2 activity, thereby facilitating RUNX2-mediated osteogenic differentiation. The indirect
pathway is independent on osteogenesis, which includes the potential negative regulation of adipogenic differentiation.
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droplets in hBMSCs. Thus, it is plausible that PKCδ in-
creases endogenous RUNX2 transcriptional activity, and
up-regulated RUNX2 facilitates RUNX2-dependent gene
transcription and osteogenesis, thereby repressing PPARγ-
dependent gene transcription and adipogenesis (Figure 6).
Meanwhile, it has been reported that the lineage commit-
ment and differentiation of transformed haematopoietic
progenitors is determined by the level of PKC activity, sug-
gesting that the regulation of PKC activity is critical for
governing the differentiation capacity of haematopoietic
progenitor cells [42]. Taken together, these findings em-
phasize the important physiological effect of PKCδ on the
relationship between bone and fat metabolism. Interest-
ingly, identical to the effects of PKCδ inhibition, the adipo-
genic phenotype as a result of AMPK inhibition during
in vitro osteogenesis of hBMSCs has also been observed
(Figure 5). Our data are in agreement with the involve-
ment of AMPK in stem cell differentiation [43], which
supports evidence that AMPK may inhibit adipogenic dif-
ferentiation by shifting stem cell fate toward osteogenic
differentiation via a PKCδ-independent pathway.
Conclusions
The results of present study demonstrate that PKCδ and
AMPK has a crucial role in regulating the balance be-
tween osteogenesis and adipogenesis of hBMSCs. Since
appropriate management of hBMSC differentiation is im-
portant for the development and maintenance of healthy
bones, this study might provide a new insight into the
regulatory mechanisms of hBMSC differentiation, furtherencouraging novel therapeutic strategies for improving
bone regeneration.
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